Beta-thalassemia

Orphanet Journal of Rare Diseases

Volumn 5, Issue 1, 2010, Pages

  Galanello, Renzo ^a   Origa, Raffaella ^a  

^a UNIVERSITY OF CAGLIARI   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

3' DESAZADESFERRITHIOCIN POLYETHER; 5 AZA 2' DEOXYCYTIDINE; ACARBOSE; ALENDRONIC ACID; ALPHA TOCOPHEROL; ANTIBIOTIC AGENT; ANTITHROMBOCYTIC AGENT; AZACITIDINE; BETA GLOBIN; BUTYRIC ACID DERIVATIVE; CALCITRIOL; CALCIUM; CHELATING AGENT; CHORIONIC GONADOTROPIN; DEFERASIROX; DEFERIPRONE; DEFEROXAMINE; ETHINYLESTRADIOL; HEPARIN; HUMAN MENOPAUSAL GONADOTROPIN; HYDROXYUREA; LEVOTHYROXINE; PAMIDRONIC ACID; PENTOXIFYLLINE; PLATELET DERIVED GROWTH FACTOR; TESTOSTERONE; TESTOSTERONE ESTER; UNCLASSIFIED DRUG; UNINDEXED DRUG; VITAMIN D; ZOLEDRONIC ACID;

AGRANULOCYTOSIS; ALPHA THALASSEMIA; ANEMIA; APLASTIC ANEMIA; ARTHRALGIA; ASTHENOSPERMIA; AZOOSPERMIA; BACTERIAL INFECTION; BETA THALASSEMIA; BLURRED VISION; BONE DYSPLASIA; BONE MALFORMATION; BONE MARROW; BONE MARROW TRANSPLANTATION; BURN; CATARACT; CAUSE OF DEATH; CHILL; CHROMOSOME 11; CLINICAL FEATURE; CLINICAL TRIAL; COLOR VISION; CONGENITAL DYSERYTHROPOIETIC ANEMIA; CREATININE BLOOD LEVEL; DELAYED PUBERTY; DEVELOPING COUNTRY; DIABETES MELLITUS; DIET; DIFFERENTIAL DIAGNOSIS; DISEASE PREDISPOSITION; DISEASE SEVERITY; DISEASE TRANSMISSION; DRUG ABSORPTION; DRUG DOSE INCREASE; DRUG ERUPTION; DRUG FEVER; ERYTHEMA; ERYTHROCYTE TRANSFUSION; ETHNICITY; EUROPEAN UNION; EVENING DOSAGE; EXTRAMEDULLARY HEMATOPOIESIS; EYE TOXICITY; FACE DYSMORPHIA; FERRITIN BLOOD LEVEL; FEVER; GALLSTONE; GASTROINTESTINAL TOXICITY; GENETIC COUNSELING; GENETIC SCREENING; GROWTH RETARDATION; HEART DISEASE; HEMATOPOIESIS; HEMOGLOBIN SYNTHESIS; HEMOGLOBINOPATHY; HEPATOSPLENOMEGALY; HUMAN; HYPOCALCEMIA; HYPOGONADISM; HYPOPARATHYROIDISM; HYPOTHYROIDISM; IMMUNIZATION; IMPAIRED GLUCOSE TOLERANCE; INCIDENCE; INJECTION SITE REACTION; IRON OVERLOAD; JAUNDICE; JUVENILE MYELOMONOCYTIC LEUKEMIA; KIDNEY FAILURE; LEG ULCER; LIFESTYLE MODIFICATION; LIVER; LIVER CIRRHOSIS; LIVER FIBROSIS; LYMPH NODE; MALAISE; MOLECULAR GENETICS; MUSCLE; NIGHT BLINDNESS; NONHUMAN; OSTEOPOROSIS; PAIN; PALLOR; PATHOPHYSIOLOGY; POINT MUTATION; PRENATAL DIAGNOSIS; PROGNOSIS; PRURITUS; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS; REVIEW; SEPSIS; SEXUAL MATURATION; SIDE EFFECT; SIDEROBLASTIC ANEMIA; SKELETAL MUSCLE; SKIN INDURATION; SPINE; SPLEEN; SPLEEN SURGERY; SPLENECTOMY; SWELLING; THALASSEMIA MAJOR; THALASSEMIA MINOR; THORAX; THROMBOCYTOSIS; THROMBOSIS; URTICARIA; VIRUS INFECTION; VISUAL ACUITY; ZINC DEFICIENCY; GENETICS;

BETA-THALASSEMIA; GENETIC COUNSELING; HUMANS; PRENATAL DIAGNOSIS;

EID: 77952432110     PISSN: None     EISSN: 17501172     Source Type: Journal    
DOI: 10.1186/1750-1172-5-11     Document Type: Review

References (94)

1. The population genetics of the hemoglobinopathies. J Flint RM Harding AJ Boyce JB Clegg, Bailliere's Clinical Hematology 1998 11 1 50 10.1016/S0950-3536(98)80069-3 (Pubitemid 29039017)
2. Changing patterns of thalassemia worldwide. EP Vichinsky, Ann N Y Acad Sci 2005 1054 18 24 10.1196/annals.1345.003 16339647
3. Thalassemia International Federation, Guidelines for the clinical management of thalassemia 2 2008 http://www.thalassemia.org.cy
4. Thalassemias and related disorders: quantitative disorders of hemoglobin synthesis. C Borgna-Pignatti R Galanello, Wintrobe's Clinical Hematology Lippincott Williams & Wilkins. Philadelphia 11 2004 42 1319 1365
5. Hepatocellular carcinoma in the thalassemia syndromes. C Borgna-Pignatti G Vergine T Lombardo MD Cappellini P Cianciulli A Maggio D Renda ME Lai A Mandas G Forni A Piga MG Bisconte, Br J Haematol 2004 124 114 117 10.1046/j.1365-2141. 2003.04732.x 14675416
6. Survival and complications in thalassemia. C Borgna-Pignatti MD Cappellini P De Stefano GC Del Vecchio GL Forni MR Gamberini R Ghilardi R Origa A Piga MA Romeo H Zhao A Cnaan, Ann N Y Acad Sci 2005 1054 40 47 10.1196/annals.1345.006 16339650
7. Cholelithiasis and Gilbert's syndrome in homozygous beta-thalassemia. R Galanello S Piras S Barella GB Leoni MD Cipollina L Perseu A Cao, Br J Haematol 2001 115 926 928 10.1046/j.1365-2141.2001.03200.x 11843828
8. Thalassemia and hypercoagulability. AT Taher ZK Otrock I Uthman MD Cappellini, Blood Rev 2008 22 283 292 10.1016/j.blre.2008.04.001 18511163
9. Final height and endocrine function in Thalassemia Intermedia. V De Sanctis A Tangerini MR Testa AL Lauriola MR Gamberini AR Cavallini F Rigolin, J Pediatr Endocrinol Metab 1998 11 965 971 10091174
10. Pregnancy outcome in patients with beta-thalassemia intermedia at two tertiary care centers, in Beirut and Milan. AH Nassar M Naja C Cesaretti B Eprassi MD Cappellini A Taher, Haematologica 2008 93 1586 1587 10.3324/haematol.13152 18698079
11. Thalassemia heart disease: a comparative evaluation of thalassemia major and thalassemia intermedia. A Aessopos D Farmakis S Deftereos M Tsironi S Tassiopoulos I Moyssakis M Karagiorga, Chest 2005 127 1523 1530 10.1378/chest.127.5.1523 15888823
12. Elastic tissue abnormalities resembling pseudoxanthoma elasticum in beta thalassemia and the sickling syndromes. A Aessopos D Farmakis D Loukopoulos, Blood 2002 99 30 35 10.1182/blood.V99.1.30 11756149
13. Dominant beta thalassaemia: molecular basis and pathophysiology. SL Thein, Br J Haematol 1992 80 273 277 10.1111/j.1365-2141.1992.tb08132.x 1581206
14. Mutations in the general transcription factor TFIIH result in beta-thalassemia in individuals with trichothiodystrophy. V Viprakasit RJ Gibbons BC Broughton JL Tolmie D Brown P Lunt RM Winter S Marinoni M Stefanini L Brueton AR Lehmann DR Higgs, Hum Mol Genet 2001 10 2797 2802 10.1093/hmg/10.24.2797 11734544 (Pubitemid 34026461)
15. Different substitutions at residue D218 of the X-linked transcription factor GATA1 lead to altered clinical severity of macrothrombocytopenia and anemia and are associated with variable skewed X inactivation. K Freson G Matthijs C Thys P Marien MF Hoylaerts J Vermylen C Van Geet, Hum Mol Genet 2002 11 147 152 10.1093/hmg/11.2.147 11809723
16. HbVar database of human hemoglobin variants and thalassemia mutations: 2007 update. B Giardine S van Baal P Kaimakis C Riemer W Miller M Samara P Kollia NP Anagnou DH Chui H Wajcman RC Hardison GP Patrinos, Hum Mutat 2007 28 206 10.1002/humu.9479 17221864
17. A Syllabus of Thalassemia Mutations. THJ Huisman MFH Carver E Baysal, The Sickle Cell Anemia Foundation, Augusta, GA 1997
18. Relationship between genotype and phenotype. Thalassemia intermedia. R Galanello A Cao, Ann N Y Acad Sci 1998 850 325 333 10.1111/j.1749-6632.1998. tb10489.x 9668554 (Pubitemid 128714088)
19. Genome-wide association study shows BCL11A associated with peristent fetal hemoglobin and amelioration of the phenotype of beta-thalassemia. M Uda R Galanello S Sanna G Lettre VG Sankaran W Chen G Usala F Busonero A Maschio G Albai MG Piras N Sestu S Lai M Dei A Mulas L Crisponi S Naitza I Asunis M Deiana R Nagaraja L Perseu S Satta MD Cipollina C Sollaino P Moi JN Hirschhorn SH Orkin GR Abecasis D Schlessinger A Cao, Proc Natl Acad Sci USA 2008 105 1620 1625 10.1073/pnas.0711566105 18245381
20. Hyperbilirubinaemia in heterozygous b-thalassemia is related to co-inherited Gilbert's syndrome. R Galanello L Perseu MA Melis L Cipollina S Barella N Giagu MP Turco O Maccioni A Cao, Br J Haematol 1997 99 433 436 10.1046/j.1365-2141.1997.3703182.x 9375768
21. Cholelithiasis in thalassemia major. R Origa R Galanello L Perseu D Tavazzi M Domenica Cappellini L Terenzani GL Forni G Quarta T Boetti A Piga, Eur J Haematol 2009 82 22 25 10.1111/j.1600-0609.2008.01162.x 19021734
22. Apolipoprotein E epsilon4 allele as a genetic risk factor for left ventricular failure in homozygous beta-thalassemia. E Economou-Petersen A Aessopos A Kladi P Flevari F Karabatsos C Fragodimitri P Nicolaidis H Vrettou D Vassilopoulos M Karagiorga-Lagana DT Kremastinos MB Petersen, Blood 1998 92 3455 3459 9787187
23. Association of heart failure in homozygous beta-thalassemia with the major histocompatibility complex. DT Kremastinos P Flevari M Spyropoulou H Vrettou D Tsiapras CG Stavropoulos-Giokas, Circulation 1999 100 2074 2078 10562263
24. The influence of hemochromatosis mutations on iron overload of thalassemia major. F Longo G Zecchina L Sbaiz R Fischer A Piga C Camaschella, Haematologica 1999 84 799 803 10477452
25. Osteoporosis in-thalassemia major patients: analysis of the genetic background. S Perrotta MD Cappellini F Bertoldo V Servedio G Iolascon L D'Agruma P Gasparini MC Siciliani A Iolascon, Br J Haematol 2000 111 461 466 10.1046/j.1365-2141.2000.02382.x 11122085
26. Bone mineral metabolism in adults with-thalassemia major and intermedia. R Dresner Pollack E Rachmilewitz A Blumenfeld M Idelson AW Goldfarb, Br J Haematol 2000 111 902 907 10.1046/j.1365-2141.2000.02392.x 11122154
27. Glutathione S-transferase gene polymorphism and cardiac iron overload in thalassemia major. R Origa S Satta G Matta R Galanello, Br J Haematol 2008 142 143 145 10.1111/j.1365-2141.2008.07175.x 18477036
28. Association of alpha globin gene quadruplication and heterozygous beta thalassemia in patients with thalassemia intermedia. MC Sollaino ME Paglietti L Perseu N Giagu D Loi R Galanello, Haematologica 2009 94 1445 1448 10.3324/haematol.2009.005728 19794088
29. 0 thalassemia trait in Sardinia. R Galanello MA Melis R Ruggeri M Addis MT Scalas L Maccioni M Furbetta A Angius T Tuveri A Cao, Hemoglobin 1979 3 33 46 10.3109/03630267909069153 457422
30. Rapid screening of multiple betaglobin gene mutations by real-time PCR on the LightCycler: application to carrier screening and prenatal diagnosis of thalassemia syndromes. C Vrettou J Traeger-Synodinos M Tzetis G Malamis E Kanavakis, Clin Chem 2003 49 769 776 10.1373/49.5.769 12709368
31. Prenatal diagnosis and screening of the haemoglobinopathies. A Cao R Galanello MC Rosatelli, Baillieres Clin Haematol 1998 11 215 238 10.1016/S0950-3536(98)80076-0 10872479
32. Identification of nucleated red blood cells in maternal circulation: a second step in screening for fetal aneuploidies and pregnancy complications. A Mavrou E Kouvidi A Antsaklis A Souka S Kitsiou Tzeli A Kolialexi, Prenat Diagn 2007 27 150 153 10.1002/pd.1640 17186566
33. Recent advances in fetal nucleic acids in maternal plasma. YM Lo, J Histochem Cytochem 2005 53 293 296 10.1369/jhc.4R6362.2005 15750005
34. Webthal. http://www.talassemia.it/sito-eng/THAL-intro-eng.html
35. Thalassemia Clinical Research Network. Complications of beta-thalassemia major in North America. MJ Cunningham EA Macklin EJ Neufeld AR Cohen, Blood 2004 104 34 39 10.1182/blood-2003-09-3167 14988152
36. Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine. C Borgna-Pignatti S Rugolotto P De Stefano H Zhao MD Cappellini GC Del Vecchio MA Romeo GL Forni MR Gamberini R Ghilardi A Piga A Cnaan, Haematologica 2004 89 1187 1193 15477202
37. Hepatic iron stores and plasma ferritin concentration in patients with sickle cell anemia and thalassemia major. GM Brittenham AR Cohen CE McLaren MB Martin PM Griffith AW Nienhuis NS Young CJ Allen DE Farrell JW Harris, Am J Hematol 1993 42 81 85 10.1002/ajh.2830420116 8416302
38. Hepatic iron concentration and total body iron stores in thalassemia major. E Angelucci GM Brittenham CE McLaren M Ripalti D Baronciani C Giardini M Galimberti P Polchi G Lucarelli, N Engl J Med 2000 343 327 331 10.1056/NEJM200008033430503 10922422
39. Variability in hepatic iron concentration measurement from needle-biopsy specimens. JP Villeneuve M Bilodeau R Lepage J Cote M Lefebvre, Journal of Hepatology 1996 25 172 177 10.1016/S0168-8278(96)80070-5 8878778
40. Cardiovascular T2-star (T2*) magnetic resonance for the early diagnosis of myocardial iron overload. LJ Anderson S Holden B Davis E Prescott CC Charrier NH Bunce DN Firmin B Wonke J Porter JM Walker DJ Pennell, Eur Heart J 2001 22 2171 2179 10.1053/euhj.2001.2822 11913479
41. Myocardial iron loading in transfusiondependent thalassemia and sickle cell disease. JC Wood JM Tyszka S Carson MD Nelson TD Coates, Blood 2004 103 1934 1936 10.1182/blood-2003-06-1919 14630822
42. Thalassemia International Federation Heart T2* Investigators. Multi-center validation of the transferability of the magnetic resonance T2* technique for the quantification of tissue iron. MA Tanner T He MA Westwood DN Firmin DJ Pennell, Haematologica 2006 91 1388 17018390
43. Noninvasive measurement and imaging of liver iron concentrations using proton magnetic resonance. TG St Pierre PR Clark W Chua-anusorn AJ Fleming GP Jeffrey JK Olynyk P Pootrakul E Robins R Lindeman, Blood 2005 105 855 861 10.1182/blood-2004-01-0177 15256427 (Pubitemid 40070775)
44. Myocardial iron clearance during reversal of siderotic cardiomyopathy with intravenous desferrioxamine: a prospective study using T2* cardiovascular magnetic resonance. LJ Anderson MA Westwood S Holden B Davis E Prescott B Wonke JB Porter JM Walker DJ Pennell, Br J Haematol 2004 127 348 355 10.1111/j.1365-2141.2004.05202.x 15491298
45. Combined chelation therapy in thalassemia major for the treatment of severe myocardial siderosis with left ventricular dysfunction. MA Tanner R Galanello C Dessi GC Smith MA Westwood A Agus M Pibiri SV Nair JM Walker DJ Pennell, J Cardiovasc Magn Reson 2008 10 12 10.1186/1532-429X-10-12 18298856
46. Monitoring long-term efficacy of iron chelation therapy by deferiprone and desferrioxamine in patients with beta-thalassemia major: application of SQUID biomagnetic liver susceptometry. R Fischer F Longo P Nielsen R Engelhardt RC Hider A Piga, Br J Haematol 2003 121 938 948 10.1046/j.1365-2141.2003.04297.x 12786807
47. Results of long-term iron-chelating therapy. V Gabutti A Piga, Acta Haematol 1996 95 26 36 10.1159/000203853 8604584
48. Deferiprone in the treatment of transfusion-dependent thalassemia: a review and perspective. R Galanello, Ther Clin Risk Manag 2003 3 795 805
49. Comparison of effects of oral deferiprone and subcutaneous desferrioxamine on myocardial iron concentrations and ventricular function in beta-thalassaemia. LJ Anderson B Wonke E Prescott S Holden JM Walker DJ Pennell, Lancet 2002 360 516 520 10.1016/S0140-6736(02)09740-4 12241655
50. Comparative effects of deferiprone and deferoxamine on survival and cardiac disease in patients with thalassemia major: a retrospective analysis. A Piga C Gaglioti E Fogliacco F Tricta, Haematologica 2003 88 489 496 12745268
51. Randomized controlledtrial of deferiprone or deferoxamine in beta-thalassemia major patients with asymptomatic myocardial siderosis. DJ Pennell V Berdoukas M Karagiorga V Ladis A Piga A Aessopos ED Gotsis MA Tanner GC Smith MA Westwood B Wonke R Galanello, Blood 2006 107 3738 3744 10.1182/blood-2005-07-2948 16352815
52. Cardiac morbidity and mortality in deferoxamine-or deferiprone-treated patients with thalassemia major. C Borgna-Pignatti MD Cappellini P De Stefano GC Del Vecchio GL Forni MR Gamberini R Ghilardi A Piga MA Romeo H Zhao A Cnaan, Blood 2006 107 3733 3737 10.1182/blood-2005-07-2933 16373663
53. Risk factors for death in patients with beta-thalassemia major: results of a case-control study. A Ceci P Baiardi M Catapano M Felisi P Cianciulli V De Sanctis GC DelVecchio C Magnano A Meo A Maggio, Haematologica 2006 91 1420 1421 16963395 (Pubitemid 44569822)
54. Combined therapy with deferiprone and desferrioxamine. B Wonke C Wright AV Hoffbrand, Br J Haematol 1998 103 361 364 10.1046/j.1365-2141.1998.01002.x 9827905
55. Combined oral and parenteral iron chelation in beta thalassemia major. K Balveer K Pryor B Wonke, Med J Malaysia 2001 55 493 497
56. Effectiveness and safety of combined iron-chelation therapy with deferoxamine and deferiprone. V Alymara D Bourantas A Chaidos P Bouranta M Gouva A Vassou E Tzouvara KL Bourantas, Hematol J 2004 5 475 479 10.1038/sj.thj. 6200550 15570288
57. Combined chelation therapy in patients with thalassemia major: a fast and effective method of reducing ferritin levels and cardiological complications [abstract]. K Farmaki G Anagnostopoulos O Platis E Gotsis P Toulas, Hematol J 2002 3 Suppl 1 79
58. Safety and efficacy of combining deferiprone and deferoxamine in iron chelation therapy in patients with thalassemia [abstract]. A Kattamis C Kassou V Ladis H Berdoussi I Papasotiriou C Kattamis, Blood 2002 100 120a 10.1182/blood.V100.1.120 (Pubitemid 35177436)
59. Combined therapy with deferiprone and desferrioxamine in thalassemia major. R Origa P Bina A Agus G Crobu E Defraia C Dessi GB Leoni PP Muroni R Galanello, Haematologica 2005 90 1309 1314 16219566
60. Combined therapy with deferiprone and desferrioxamine successfully regresses severe heart failure in patients withbeta-thalassemia major. KH Wu JS Chang CH Tsai CT Peng, Ann Hematol 2004 83 471 473 10.1007/s00277-003-0820-0 14658011
61. Reversal of heart failure in thalassemia major by combined chelation therapy: a case report. M Tsironi S Deftereos P Andriopoulos D Farmakis J Meletis A Aessopos, Eur J Haematol 2005 74 84 85 10.1111/j.1600-0609.2004.00335. x 15613114
62. Effects of combined deferiprone and desferrioxamine iron chelating therapy in beta-thalassemia major end-stage heart failure: a case report. M Porcu N Landis S Salis M Corda P Orru E Serra B Usai G Matta R Galanello, Eur J Heart Fail 2007 9 320 322 10.1016/j.ejheart.2006.08.006 17029959
63. A randomized, placebo-controlled, double-blind trial of the effect of combined therapy with deferoxamine and deferiprone on myocardial iron in thalassemia major using cardiovascular magnetic resonance. MA Tanner R Galanello C Dessi GC Smith MA Westwood A Agus M Roughton R Assomull SV Nair JM Walker DJ Pennell, Circulation 2007 115 1876 1884 10.1161/CIRCULATIONAHA.106.648790 17372174
64. A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with beta-thalassemia. MD Cappellini A Cohen A Piga M Bejaoui S Perrotta L Agaoglu Y Aydinok A Kattamis Y Kilinc J Porter M Capra R Galanello S Fattoum G Drelichman C Magnano M Verissimo M Athanassiou-Metaxa P Giardina A Kourakli-Symeonidis G Janka-Schaub T Coates C Vermylen N Olivieri I Thuret H Opitz C Ressayre-Djaffer P Marks D Alberti, Blood 2006 107 3455 3462 10.1182/blood-2005-08-3430 16352812
65. Once-daily oral deferasirox for the treatment of transfusional iron overload. R Galanello R Origa, Ex Rev of Clin Pharma 2008 1 231 240 10.1586/17512433.1.2.231
66. Long-term experience with deferasirox (ICL670), a once-daily oral iron chelator, in the treatment of transfusional iron overload. MD Cappellini A Taher, Expert Opin Pharmacother 2008 9 2391 2402 10.1517/14656566.9.13.2391 18710363
67. Exjade (deferasirox) Summary of product characteristics. Novartis Pharma AG. 2006 http://www.ema.europa.eu/humandocs/PDFs/EPAR/exjade/H-670-en8.pdf
68. Italian Society of Hematology practice guidelines for the management of iron overload in thalassemia major and related disorders. E Angelucci G Barosi C Camaschella MD Cappellini M Cazzola R Galanello M Marchetti A Piga S Tura, Haematologica 2008 93 741 752 10.3324/haematol.12413 18413891
69. Standards for the Clinical Care of Children and Adults with Thalassaemia in the UK-Revised 2008 edition. U.K. Thalassemia Society, http://www.ukts.org/ pdfs/awareness/ukts-standards-2008.pdf
70. Basal and stimulated levels of growth hormone, insulin-like growth factor-I (IGF-I), IGF-I binding and IGF-binding proteins in betathalassemia major. I Karydis M Karagiorga-Lagana C Nounopoulos G Tolis, J Pediatr Endocrinol Metab 2004 17 17 25 14960017
71. Growth hormone (GH) deficiency in patients with beta thalassemia major and the efficacy of recombinant GH treatment. KH Wu FJ Tsai CT Peng, Ann Hematol 2003 82 637 640 10.1007/s00277-003-0712-3 12898188
72. Growth and puberty and its management in thalassemia. V De Sanctis, Horm Res 2002 58 72 79 10.1159/000064766 12373018
73. Clinical experience using the Androderm testosterone transdermal system in hypogonadal adolescents and young men with beta-thalassemia major. V De Sanctis C Vullo L Urso F Rigolin A Cavallini K Caramelli C Daugherty N Mazer, J Pediatr Endocrinol Metab 1998 11 891 900 10091163
74. Update on fertility in thalassemia major. N Skordis L Petrikkos M Toumba M Hadjigavriel M Sitarou A Kolnakou G Skordos E Pangalou S Christou, Pediatr Endocrinol Rev 2004 2 296 302 16462715
75. Pregnancy and betathalassemia: an Italian multicentric experience. R Origa A Piga G Quarta G Forni F Longo A Melpignano R Galanello, Haematologica 2010 95 376 81 10.3324/haematol.2009.012393 19903676
76. Normalisation of total body iron load with very intensive combined chelation reverses cardiac and endocrine complications of thalassaemia major. K Farmaki I Tzoumari C Pappa G Chouliaras V Berdoukas, Br J Haematol 2010 148 466 475 10.1111/j.1365-2141.2009.07970.x 19912219
77. Effects of acarbose in patients with beta-thalassemia major and abnormal glucose homeostasis. A Mangiagli S Campisi V De Sanctis MC Nicoletti G Cardinale MC Galati G Raiola P Rigano A Saviano Study Group of the Italian Pediatric and Diabetes Society (SIEDP) on Endocrine Complications in Non-Endocrine Disease, Pediatr Endocrinol Rev 2004 2 285 291 16462713
78. Effect of enhanced iron chelation therapy on glucose metabolism in patients with beta-thalassaemia major. K Farmaki N Angelopoulos G Anagnostopoulos E Gotsis G Rombopoulos G Tolis, Br J Haematol 2006 134 438 444 10.1111/j.1365-2141.2006.06203.x 16822284
79. Bisphosphonates in the treatment of thalassemia-associated osteoporosis. A Gaudio N Morabito A Xourafa I Macri A Meo S Morgante A Trifiletti A Lasco N Frisina, J Endocrinol Invest 2008 31 181 184 18362512
80. Stem cell transplantation for hemoglobinopathies. J Gaziev G Lucarelli, Curr Opin Pediatr 2003 15 24 31 10.1097/00008480-200302000-00005 12544268
81. Unrelated bone marrow transplantation for beta-thalassemia patients: The experience of the Italian Bone Marrow Transplant Group. G La Nasa F Argiolu C Giardini A Pession F Fagioli G Caocci A Vacca P De Stefano E Piras A Ledda A Piroddi R Littera S Nesci F Locatelli, Ann N Y Acad Sci 2005 1054 186 195 10.1196/annals.1345.023 16339665
82. Related umbilical cord blood transplantation in patients with thalassemia and sickle cell disease. F Locatelli V Rocha W Reed F Bernaudin M Ertem S Grafakos B Brichard X Li A Nagler G Giorgiani PR Haut JA Brochstein DJ Nugent J Blatt P Woodard J Kurtzberg CM Rubin R Miniero P Lutz T Raja I Roberts AM Will I Yaniv C Vermylen N Tannoia F Garnier I Ionescu MC Walters BH Lubin E Gluckman, Blood 2003 101 2137 2143 10.1182/blood-2002-07-2090 12424197
83. Cord blood stem cell transplantation for haemoglobinopathies. FO Pinto I Roberts, Br J Haematol 2008 141 309 324 18307566
84. Fetal HLA typing in beta thalassemia: implications for haemopoietic stem-cell transplantation. MG Orofino F Argiolu MA Sanna MC Rosatelli T Tuveri MT Scalas M Badiali P Cossu R Puddu ME Lai A Cao, Lancet 2003 362 41 42 10.1016/S0140-6736(03)13806-8 12853199
85. Modern treatment of thalassaemia intermedia. C Borgna-Pignatti, Br J Haematol 2007 138 291 304 10.1111/j.1365-2141.2007.06654.x 17565568
86. Liver iron concentrations and urinary hepcidin in beta-thalassemia. R Origa R Galanello T Ganz N Giagu L Maccioni G Faa E Nemeth, Haematologica 2007 92 583 588 10.3324/haematol.10842 17488680
87. Understanding mechanisms of gamma-globin gene regulation to develop strategies for pharmacological fetal hemoglobin induction. BS Pace S Zein, Dev Dyn 2006 235 1727 1737 10.1002/dvdy.20802 16607652
88. Hydroxycarbamide can eliminate transfusion requirements in children with severe beta-thalassemia. M Bradai MT Abad S Pissard F Lamraoui L Skopinski M de Montalembert, Blood 2003 102 1529 1530 10.1182/blood-2003-01-0117 12702505
89. Response to hydroxycarbamidetreatment in Iranian transfusion-dependent beta-thalassemia patients. M Yavarian M Karimi E Bakker CL Harteveld PC Giordano, Haematologica 2004 89 1172 1178 15477200
90. Therapeutic options for patients with severe-thalassemia: the need for globin gene therapy. M Sadelain F Boulad R Galanello P Giardina F Locatelli A Maggio S Rivella I Riviere J Tisdale, Hum Gene Ther 2007 18 1 9 10.1089/hum.2006.151 17173507
91. Successful correction of the human beta-thalassemia major phenotype using a lentiviral vector. G Puthenveetil J Scholes D Carbonell N Qureshi P Xia L Zeng S Li Y Yu AL Hiti JK Yee P Malik, Blood 2004 104 3445 3453 10.1182/blood-2004-04-1427 15292064
92. Thalassemia minor, the Gilbert mutation, and the risk of gallstones. C Borgna-Pignatti F Rigon L Merlo R Chakrok R Micciolo L Perseu R Galanello, Haematologica 2003 88 1106 1109 14555305
93. Survival of medically treated thalassemia patients in Cyprus. Trends and risk factors over the period 1980-2004. P Telfer PG Coen S Christou M Hadjigavriel A Kolnakou E Pangalou N Pavlides M Psiloines K Simamonian G Skordos M Sitarou M Angastiniotis, Haematologica 2006 91 1187 1192 16956817
94. Improved survival of thalassaemia major in the UK and relation to T2* cardiovascular magnetic resonance. B Modell M Khan M Darlison MA Westwood D Ingram DJ Pennell, J Cardiovasc Magn Reson 2008 10 42 10.1186/1532-429X-10-42 18817553